Our lead compound, APX3330, an oral anticancer agent, has shown preclinical efficacy against a variety of APE1-expressing tumors. APX3330 safety has been confirmed in 10 Phase I/II human studies of non-cancer indications with more than 422 patients.
The phase I oncology study of APX 3330 is ready to initiate enrollment and will commence in 2017:
- Complete IND approved by FDA
- First site has IRB approval
- Additional sites being developed
- Clinical supplies are ready to ship